American vs Chinese Skullcap: Two Different Herbs
There is no single herb called “skullcap.” There are at least two herbs in wide commercial use that answer to the name, they belong to the same genus and almost nothing else, and mixing them up is the most common mistake made about this plant — by shoppers, by supplement marketers, and sometimes by health writers who ought to know better. American skullcap is Scutellaria lateriflora: a North American mint-family plant whose dried aerial parts (leaves, stems, flowering tops) are the classic Western nervine, taken as a tea or tincture for anxious tension and restless sleep. Chinese skullcap is Scutellaria baicalensis, called huang qin in traditional Chinese medicine: a different species whose dried root is one of the most-used herbs in East Asian formula medicine, and whose flavones — baicalin, baicalein and wogonin — carry a very large modern laboratory literature that has essentially nothing to do with calming the nerves.
This page keeps them apart. Every claim below is tagged with the species, the plant part, and the evidence tier — randomized clinical trial, preliminary (animal or in-vitro), or traditional use only — because the single most useful discipline when reading about skullcap is refusing to let a finding about one plant migrate quietly onto the other.
Table of Contents
- Two Plants, One Common Name
- Botany: Telling Them Apart
- Aerial Tops vs. Root: Why the Part Matters
- Different Chemistry, Overlapping Names
- Two Separate Traditions
- What Each One Is Actually Used For
- How the Conflation Happens
- Reading a Label: Species, Part, Extract
- Evidence Tiers Side by Side
- Safety Differs Between the Two
- Practical Rules for Readers
- Other Scutellaria You May Meet
- Key Research Papers
- Connections
- Featured Videos
Two Plants, One Common Name
The genus Scutellaria holds something on the order of three to four hundred accepted species, distributed across most of the temperate world. Two of them dominate the herbal marketplace, and English gave them the same common name because both share the same odd botanical feature: a small dish- or helmet-shaped bump on the upper lip of the calyx, the green cup that holds the flower. Scutella is Latin for “little dish.” Early botanists thought the bump resembled the close-fitting cap worn under a helmet, and the name stuck to the whole genus.
That is where the resemblance ends in any way that matters to someone taking the herb. Consider what actually differs:
- Species. S. lateriflora (American, Virginia, blue, or “mad-dog” skullcap) versus S. baicalensis (Chinese, Baikal, or Baical skullcap; huang qin).
- Native range. Damp meadows, marsh edges and streambanks across eastern and central North America, versus the dry grasslands and stony slopes of northeast China, Mongolia, Korea, Japan and eastern Siberia around Lake Baikal — which is where the epithet baicalensis comes from.
- Part harvested. Aerial parts in bloom, versus the peeled and dried root.
- Tradition of use. Nineteenth-century North American Eclectic and folk practice, versus roughly two millennia of Chinese formula medicine.
- Category of use. A calming nervine, versus a bitter cold herb for what Chinese medicine calls damp heat — the inflammatory, feverish, infectious end of the diagnostic map.
- Chemistry. Overlapping flavonoid families but wildly different concentrations, plus compounds each plant has that the other essentially does not.
Six differences in a row is not a nuance. These are two different medicines that happen to share a surname.
Botany: Telling Them Apart
Scutellaria lateriflora is a slender perennial, usually knee-high or a little more, with the square stems and opposite paired leaves typical of the mint family. Its species name is the best identification hint available: lateriflora means “side-flowering,” and the plant carries its small pale blue to lavender flowers in one-sided racemes that emerge from the leaf axils along the stem rather than in a single showy terminal spike. The leaves are toothed, thin, and stalked. The whole plant is nearly odourless when fresh — unusual for a mint — and tastes faintly bitter. It has no aromatic oil to speak of, which is one reason it does not smell like the peppermint or thyme a shopper might expect from Lamiaceae.
Scutellaria baicalensis is a tougher, more upright plant of dry ground, with narrow, nearly stalkless lance-shaped leaves and larger flowers — typically deep violet-blue to purple — carried in a dense one-sided terminal spike. The feature that matters commercially is underground: a thick, fleshy taproot that turns a striking yellow inside. That colour is the flavone content, and it is the origin of the Chinese name: huang qin means, roughly, “yellow herb” or “golden herb.” If you cut open a piece of dried huang qin root and it is not yellow, something is wrong with it.
Evidence tier: botanical description, not a health claim. None of this is disputed, but note that visual identification is only useful on whole plant material. Once either herb has been dried and milled to powder, the distinguishing features are gone and you are relying entirely on the supply chain — which is exactly the vulnerability discussed on the liver safety page.
Aerial Tops vs. Root: Why the Part Matters
Plant part is not a detail. Within a single species, root, leaf, seed and flower can differ in composition as much as two unrelated plants, because a root that stores defensive compounds through a winter is doing a chemically different job from a leaf that photosynthesises for one season. Willow bark and willow leaf, cinnamon bark and cinnamon leaf, ginseng root and ginseng leaf are all standard examples.
For skullcap, the split runs cleanly along the species line and doubles the confusion:
- American skullcap uses the aerial parts. Traditional harvest is at or just after flowering, with the leaves, stems and flowering tops dried whole or extracted fresh in alcohol. The root of S. lateriflora is not the article of commerce and has essentially no tradition of use.
- Chinese skullcap uses the root. Roots are typically lifted from plants three or more years old, cleaned, sometimes peeled, sliced and dried; some preparations are additionally stir-fried or wine-processed, which Chinese medicine treats as changing the herb's action. The aerial parts of S. baicalensis are not the standard medicinal article.
So “skullcap” on a label is doubly ambiguous: it does not tell you which species, and it does not tell you which organ of that species. A capsule labelled “Skullcap 400 mg” with no Latin name and no part designation is genuinely uninterpretable. That is not pedantry — a reader hoping for a mild evening sedative could easily end up with a bitter root extract that has no such tradition behind it.
Different Chemistry, Overlapping Names
Here is the trap that catches even careful readers. Both plants contain flavonoids, and some of the named compounds overlap — which makes it feel legitimate to read across from one to the other. It is not, because the concentrations are not remotely comparable and each plant carries markers the other lacks.
S. baicalensis root is one of the richest known plant sources of a small group of flavones: baicalin (the glucuronide) and its aglycone baicalein, plus wogonoside and wogonin. In good-quality root these are not trace constituents; baicalin alone commonly runs to several percent of dry weight, and pharmacopoeial standards for huang qin are written around a minimum baicalin content. Essentially the entire modern research literature on Chinese skullcap — thousands of papers — is about these flavones. The chemistry and biology of the genus, and of these compounds in particular, were reviewed in The genus Scutellaria: an ethnopharmacological and phytochemical review in the Journal of Ethnopharmacology in 2010 (PubMed PMID: 20064593), and the plant's biosynthetic route to these unusual flavones was described in Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants (Science Bulletin, 2016; PubMed PMID: 27730005).
S. lateriflora aerial parts do contain baicalin and baicalein, which is the source of most of the confusion — but in far smaller amounts, alongside a different overall profile. The most-cited chemical characterisation, Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties (Phytomedicine, 2003; PubMed PMID: 14692724), measured the flavone baicalin (40 mg per gram of a 50% ethanol extract) and its aglycone baicalein (33 mg per gram of a 95% ethanol extract) — figures per gram of concentrated extract, not of the dried herb — and, notably, measurable amounts of the amino acids gamma-aminobutyric acid (GABA) (about 1.6 mg per gram of water and ethanol extracts) and glutamine (31 mg per gram of a water extract) — something not part of the huang qin story at all. The same paper's anxiety-type behaviour tests (open-field and elevated plus-maze) were done in rats given the extract by mouth. Later work identified twelve phenolic marker compounds (ten flavonoids and two phenylethanoid glycosides), found that commercial American skullcap products contained similar constituents but in widely varying amounts and proportions, and tested anticonvulsant activity in rats, in Characterization of chemical ingredients and anticonvulsant activity of American skullcap (Scutellaria lateriflora) (Phytomedicine, 2009; PubMed PMID: 18786819), and a separate paper found that S. lateriflora flavonoids inhibited binding at the serotonin 5-HT7 receptor (Journal of Natural Products, 2003; PubMed PMID: 12713409).
Two further complications are worth holding in mind:
- Extraction method changes what you get. Hot-water infusion, 70% ethanol tincture, accelerated solvent extraction and supercritical CO2 do not pull the same compounds in the same ratios out of S. lateriflora; this was measured directly in a 2005 Journal of Agricultural and Food Chemistry comparison of extraction methods (PubMed PMID: 15826062). A result obtained with one preparation does not automatically transfer to another.
- Growing conditions and harvest timing move the numbers. Flavonoid content in both species varies with cultivar, soil, season and age of the plant, which is part of why standardisation matters more for herbs than for single-molecule drugs.
Evidence tier for this section: analytical chemistry and in-vitro pharmacology (preliminary). Knowing that a plant contains a compound that binds a receptor in a dish is a starting point for research, not a demonstration that swallowing the plant does anything in a person.
Two Separate Traditions
American skullcap came into Western herbal practice from North American folk and Indigenous use and was then taken up enthusiastically by the nineteenth-century Eclectic physicians, a school of American doctors who worked largely with plant medicines. In their materia medica it was a premier nervine: an herb for “nervous excitability,” irritability, nervous exhaustion, tension headache and the wound-up state that prevents sleep. It also carried a spectacular piece of misinformation — promoted from the late 1700s as a cure for rabies, hence the folk name mad-dog weed. It does not treat rabies; nothing herbal does, and a possible rabies exposure is a medical emergency requiring prompt post-exposure vaccination. The name is a historical curiosity only.
Chinese skullcap has a documented place in Chinese formula medicine going back to the classical era. As huang qin it is classed among the bitter, cold, heat-clearing and damp-drying herbs, and it appears in a long list of named formulas — typically alongside herbs such as huang lian (Coptis, a berberine-containing root) and huang bai, or in combinations for the digestive tract, the respiratory tract, and in classical obstetric use. It is a workhorse formula ingredient, rarely a solo herb, and its traditional indications are inflammatory and infectious rather than psychological.
Evidence tier: traditional use only. Long use is a real form of knowledge about tolerability and about which complaints a herb was thought to suit. It is not evidence of efficacy by modern standards, and it is emphatically not interchangeable across traditions — a Western nervine indication cannot be transferred to a Chinese heat-clearing root because both plants are called skullcap.
What Each One Is Actually Used For
Stated plainly, with tiers attached:
- S. lateriflora, aerial parts — anxiety and nervous tension. Traditional use plus two small placebo-controlled human trials in healthy volunteers: a 2003 study reported reduced anxiety, while the larger 2014 trial found better overall mood but no difference from placebo on an anxiety scale. This is among the best-supported uses of either species in humans, and it is still a thin literature. Covered in detail on Skullcap for Anxiety and Sleep.
- S. lateriflora, aerial parts — sleep. Largely traditional use, plus the reasonable inference that easing evening anxiety helps sleep indirectly. One randomized clinical trial now exists: in a 2025 single-centre, double-blind, placebo-controlled crossover study, 66 adults aged 18 to 70 with mild-to-moderate primary insomnia took an S. lateriflora extract-based supplement (400 mg a day) or placebo for 56 days each; the researchers reported better Pittsburgh Sleep Quality Index scores and better sleep onset latency, sleep efficiency and total sleep time, and no participant reported side effects (PubMed PMID: 40362800). It is one study of one product and has not yet been repeated.
- S. baicalensis, root — inflammation and related targets. A very large preliminary literature on baicalin, baicalein and wogonin in cells and animals, spanning inflammatory signalling, oxidative stress, neuroprotection and oncology models. Human trial evidence is far scarcer than the volume of papers suggests. Covered on Baicalin and the Chinese Skullcap Research.
- S. baicalensis, root — traditional heat-clearing indications. Traditional use only, within formulas, for conditions Chinese medicine frames as damp heat.
Notice what is absent from that list: there is no established tradition and no meaningful trial base for using Chinese skullcap root as a calming evening herb, and none for using American skullcap aerial parts as an anti-inflammatory. If you see either claim, the odds are good that someone has read across the species line.
The closest test so far of Chinese skullcap root for stress used a combination: in a 2025 randomized, double-blind, placebo-controlled crossover trial, 43 stressed but otherwise healthy adults (35 analysed) took a tablet combining S. baicalensis root and hawthorn (Crataegus laevigata) fruit extracts with magnesium and chromium, or placebo, for 15 days each; the supplement reduced total mood disturbance, anger/hostility and trait anxiety scores, and no serious side effects were reported (PubMed PMID: 41194549). The study sponsor employed one of the authors, and a four-ingredient tablet cannot show what skullcap alone does. Tier: randomized clinical trial of a combination product.
How the Conflation Happens
The mix-up is not random; it follows predictable routes, and recognising them is most of the defence.
- The shared baicalin. Because S. lateriflora contains some baicalin and S. baicalensis contains a great deal of it, an article can cite baicalin research and place it under a heading about the calming herb without technically stating a falsehood. The result is still misleading: the doses, the plant part and the effect being studied all come from the other plant.
- Search-engine and database collapse. A query for “skullcap” returns both species intermixed. Because huang qin research outnumbers lateriflora research by a very wide margin, an unqualified search returns overwhelmingly Chinese skullcap material even to someone looking for the nervine.
- Marketing convenience. Baicalin research reads more impressively than three small anxiety trials. A supplement that contains one species can be described using the literature of the other unless the label and the copy are disciplined.
- Genuine substitution in the supply chain. Beyond marketing sloppiness, there is documented concern about what is actually in skullcap products. Identity issues surrounding American skullcap (Scutellaria lateriflora) and an optimised high performance liquid chromatography method to authenticate commercially available products (Journal of Herbal Medicine, 2013; doi:10.1016/j.hermed.2013.02.001) addresses this directly, and the American Herbal Pharmacopoeia monograph Skullcap Scutellaria lateriflora L.: an American nervine (Journal of Herbal Medicine, 2012; doi:10.1016/j.hermed.2012.06.004) treats identity and authentication as central rather than incidental.
- Older herbals and secondary sources. Some pre-modern and popular texts simply say “skullcap” without a binomial, so a modern writer quoting them inherits the ambiguity and may resolve it wrongly.
Reading a Label: Species, Part, Extract
A clearly labelled skullcap product states five things. With fewer, the buyer is guessing.
- The binomial. Scutellaria lateriflora or Scutellaria baicalensis, printed on the label — not inferred from a picture or a marketing phrase.
- The plant part. “Aerial parts” / “herb” / “leaf and flowering top” for the American species; “root” for the Chinese one. A part designation that contradicts the species — “S. lateriflora root” is a red flag about the maker's competence.
- The preparation and ratio. Dried herb, 1:2 or 1:5 tincture, or a concentrated extract at a stated ratio. “Extract” alone means nothing.
- Any standardisation marker. For huang qin, a stated baicalin percentage is meaningful. For S. lateriflora, standardisation is less established, so the identity of the raw material carries more weight than any marker figure.
- Identity testing. Some statement that the raw herb's identity was verified, ideally with third-party certification. Marks from third-party quality-testing programmes address manufacturing quality rather than clinical efficacy, but for a herb with a documented substitution history that is exactly the risk that matters.
Combination products deserve extra scepticism, because a blend can list “skullcap” among a dozen botanicals with no binomial anywhere on the panel. If you cannot tell which species you are taking, you cannot look up either its evidence or its cautions.
Evidence Tiers Side by Side
Setting the two herbs against each other on the same scale is clarifying, and slightly deflating for both.
American skullcap, aerial parts. Randomized human data exist but are few and small. The most cited is American skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers (Phytotherapy Research, 2014; PubMed PMID: 23878109), preceded by a smaller volunteer study in Alternative Therapies in Health and Medicine in 2003 (PubMed PMID: 12652886) that reported reduced anxiety. In the 2014 trial, 43 healthy volunteers took 350 mg of S. lateriflora three times a day and a placebo for two weeks each; overall mood (Total Mood Disturbance on the Profile of Mood States) improved from starting scores with skullcap but not with placebo, without any loss of energy or thinking ability, while anxiety scores (Beck Anxiety Inventory) did not differ from placebo (p = 0.191). Most participants were not anxious to begin with: 81% scored as mildly anxious or less. Both studies were in healthy volunteers rather than people with diagnosed anxiety disorders. So: a modest, human-tested effect on mood, an anxiety signal from one small early study, and no basis for claims about treating an anxiety disorder.
Chinese skullcap, root. An enormous preclinical literature and a much thinner clinical one. Reviews such as New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents wogonin, baicalein and baicalin (Cancer Treatment Reviews, 2009; PubMed PMID: 19004559) survey hundreds of cell and animal findings. Pharmacokinetic work such as Baicalin, an emerging multi-therapeutic agent (Xenobiotica, 2010; PubMed PMID: 20230189) documents the awkward absorption behaviour that stands between those findings and a human effect. Baicalein itself has entered human drug testing: in a 2021 randomized, double-blind, placebo-controlled multiple-ascending-dose study, 36 healthy Chinese adults took baicalein tablets of 200, 400 or 600 mg or placebo; the tablets were generally safe and well tolerated, all side effects were mild except one moderate fever judged unrelated to baicalein, and blood levels peaked within 2 hours (PubMed PMID: 34156161). The researchers describe baicalein as an inhibitor of the influenza virus and ran the study to prepare for phase II trials. So: a large and genuinely interesting mechanistic body of work, and not a demonstrated treatment for anything in people.
The honest summary is that the American species has a little weak human evidence for mood and, since 2025, a single sleep trial, and the Chinese species has a mountain of laboratory evidence for many uses and little human confirmation. Neither profile supports confident therapeutic claims, and they are not additive.
Safety Differs Between the Two
Because the plants differ, their risk profiles differ, and the differences are not intuitive.
- American skullcap's headline risk is adulteration, not intrinsic toxicity. Historic reports of liver injury from “skullcap” products are widely attributed to substitution with Teucrium species (germander), which is genuinely hepatotoxic. That distinction cuts both ways: it partly exonerates the herb, and it means an unverified product carries a real risk a properly identified one does not. The full story is on the germander and liver safety page.
- American skullcap has an additive-sedation concern. Because it is used for its calming effect, combining it with prescription anxiolytics or hypnotics, other sedating herbs such as valerian or kava, or alcohol can stack effects.
- Chinese skullcap has its own liver signal. Baicalin-containing products have appeared in hepatotoxicity reports, most prominently the flavocoxid preparations that combined S. baicalensis baicalin with catechins; a case series of liver injury from that product was published in Annals of Internal Medicine in 2012 (PubMed PMID: 22711078). Among 877 people enrolled in the US Drug-Induced Liver Injury Network prospective study, 4 had liver injury suspected to have been caused by flavocoxid: all were women aged 57 to 68, all developed signs of liver injury 1 to 3 months after starting it, and all recovered, with liver tests back to normal 3 to 12 weeks after stopping. This is a different problem from germander substitution: here the implicated ingredient is the herb itself.
- A trial in people with diabetes adds a human liver signal. In a randomized crossover trial, people with type 2 diabetes already taking metformin added S. baicalensis (3.52 g a day) or placebo for 8 weeks each; the researchers reported better glucose tolerance than with placebo and large rises in the gut bacteria Lactobacillus and Akkermansia — and some participants showed high liver enzyme levels after taking the herb (PubMed PMID: 31770016).
- Both raise drug-interaction questions. Flavonoid-rich extracts can modulate cytochrome P450 enzymes and drug transporters, which matters most for people on narrow-therapeutic-index medications.
- Neither is established as safe in pregnancy or breastfeeding. Chinese skullcap has traditional obstetric uses within formulas, which is not the same as modern safety data; there are no modern safety studies of either species in pregnancy or breastfeeding.
Practical Rules for Readers
Five habits that prevent almost every skullcap error:
- “Which one?” comes first. Any claim about skullcap that does not name a species is not yet a claim you can evaluate.
- “Which part?” comes second. Root and aerial parts are different medicines even within one species.
- Cross-species mechanism talk is a warning sign. If a page about calming and sleep starts explaining anti-inflammatory signalling pathways, it has probably drifted into baicalensis literature.
- The binomial is the best search term. Typing Scutellaria lateriflora rather than “skullcap” into PubMed is the single most effective filter available.
- Identity is a safety feature. For this particular herb, knowing what is in the bottle is not a quality preference; it is the main safety intervention.
Other Scutellaria You May Meet
Two species dominate commerce, but a few others appear in regional practice and occasionally in the literature, which adds a further reason to insist on binomials. Scutellaria galericulata, the common or marsh skullcap, is a widespread Eurasian and North American species sometimes gathered as a substitute for S. lateriflora — a substitution of one skullcap for another rather than an adulteration with a toxic plant, but still not the herb the tradition describes. Scutellaria barbata (ban zhi lian) is a separate Chinese medicinal used quite differently from huang qin and appears in its own oncology-focused laboratory literature. Several southwestern North American and Mediterranean species turn up in local use.
The practical implication is unchanged: within a genus this large, the common name carries almost no information. Genus-level reviews such as the 2010 Journal of Ethnopharmacology survey of Scutellaria (PubMed PMID: 20064593) exist precisely because the species-level differences are large enough to need cataloguing. For plant-name checks, the Royal Botanic Gardens Kew's Plants of the World Online and the USDA PLANTS Database are the standard free references.
Key Research Papers
Each entry below links its PubMed record, or its DOI where the paper is not indexed in PubMed. Titles, journals and years are given as published.
- American skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers. Phytotherapy Research, 2014. The most-cited human trial of the American species (43 healthy volunteers, 350 mg three times a day, two weeks per arm); reported improved overall mood (Profile of Mood States) without loss of energy or cognition, while anxiety scores (Beck Anxiety Inventory) did not differ from placebo. Tier: randomized clinical trial, healthy volunteers, aerial parts. PubMed PMID: 23878109
- An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Alternative Therapies in Health and Medicine, 2003. Earlier, smaller volunteer study reporting reduced anxiety measures. Tier: small controlled human study, aerial parts. PubMed PMID: 12652886
- Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties. Phytomedicine, 2003. Characterised the aerial-part constituents — including baicalin, baicalein and measurable GABA and glutamine — alongside anxiolytic-type activity in rats. Tier: analytical chemistry plus preclinical. PubMed PMID: 14692724
- Characterization of chemical ingredients and anticonvulsant activity of American skullcap (Scutellaria lateriflora). Phytomedicine, 2009. Twelve phenolic marker compounds, wide variation in content between commercial products, and anticonvulsant activity in rats. Tier: preliminary, animal. PubMed PMID: 18786819
- Inhibition of [3H]-LSD binding to 5-HT7 receptors by flavonoids from Scutellaria lateriflora. Journal of Natural Products, 2003. Serotonin-receptor interaction offering a second candidate mechanism beyond GABA. Tier: in-vitro. PubMed PMID: 12713409
- Comparison of the chemical composition of extracts from Scutellaria lateriflora using accelerated solvent extraction and supercritical fluid extraction versus standard hot water or 70% ethanol extraction. Journal of Agricultural and Food Chemistry, 2005. Demonstrates that preparation method changes the constituent profile. Tier: analytical chemistry. PubMed PMID: 15826062
- Skullcap Scutellaria lateriflora L.: an American nervine. Journal of Herbal Medicine, 2012. The American Herbal Pharmacopoeia monograph: traditional use, chemistry, identity and adulteration. Tier: monograph review. doi:10.1016/j.hermed.2012.06.004
- Identity issues surrounding American skullcap (Scutellaria lateriflora) and an optimised high performance liquid chromatography method to authenticate commercially available products. Journal of Herbal Medicine, 2013;3(2):57-64. Examines substitution and contamination risk in the commercial supply. Tier: quality-control analysis. doi:10.1016/j.hermed.2013.02.001
- The genus Scutellaria: an ethnopharmacological and phytochemical review. Journal of Ethnopharmacology, 2010. Genus-wide survey documenting how far species differ in chemistry and use. Tier: review. PubMed PMID: 20064593
- Scutellaria baicalensis, the golden herb from the garden of Chinese medicinal plants. Science Bulletin, 2016. Why huang qin root accumulates such unusual quantities of baicalin and wogonin. Tier: plant-biochemistry review. PubMed PMID: 27730005
- New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treatment Reviews, 2009. Scale of the Chinese-skullcap preclinical literature, and its distance from clinical practice. Tier: preclinical review. PubMed PMID: 19004559
- Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Annals of Internal Medicine, 2012. Liver injury with a baicalin-containing combination product — the Chinese-species safety signal. Tier: clinical case series. PubMed PMID: 22711078
- Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Annals of Internal Medicine, 1992. The germander liver-injury cluster behind the adulteration story. Tier: clinical case series. PubMed PMID: 1605427
- Efficacy and Tolerability of a Chemically Characterized Scutellaria lateriflora L. Extract-Based Food Supplement for Sleep Management: A Single-Center, Controlled, Randomized, Crossover, Double-Blind Clinical Trial. Nutrients, 2025. 66 adults with mild-to-moderate primary insomnia, 400 mg a day for 56 days; better sleep-quality scores, no side effects reported. Tier: randomized clinical trial, one product. PubMed PMID: 40362800
- Effects of a Scutellaria baicalensis/Crataegus laevigata, magnesium and chromium supplement on stressed individuals: A randomised, double-blind, placebo-controlled, crossover trial. Journal of Psychopharmacology, 2025. Chinese skullcap root inside a four-ingredient tablet; lower mood-disturbance and trait-anxiety scores after 15 days. Tier: randomized clinical trial, combination product. PubMed PMID: 41194549
- Combined effects of Scutellaria baicalensis with metformin on glucose tolerance of patients with type 2 diabetes via gut microbiota modulation. American Journal of Physiology – Endocrinology and Metabolism, 2020. Crossover trial alongside metformin; some participants had high liver enzymes after the herb. Tier: randomized clinical trial. PubMed PMID: 31770016
- Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single-center, randomized, double-blind, placebo-controlled multiple-ascending-dose study. Clinical and Translational Science, 2021. Baicalein tablets of 200–600 mg in 36 healthy adults; generally well tolerated, peak blood levels within 2 hours. Tier: phase I drug study. PubMed PMID: 34156161
External Resources
- NIH National Center for Complementary and Integrative Health — plain-language herb summaries and safety notes.
- NIH Office of Dietary Supplements — supplement fact sheets and label-reading guidance.
- PubMed — search with the binomial, not the common name.
- Plants of the World Online (Kew) — authoritative botanical names and distributions.
- USDA PLANTS Database — North American species records.
- American Botanical Council — botanical adulterants and identity programmes.
Connections
- All Herbs
- Skullcap (main article)
- Skullcap Benefits Hub
- Skullcap for Anxiety and Sleep
- Baicalin and Chinese Skullcap Research
- Germander Adulteration and Liver Injury
- Valerian
- Passionflower
- Lemon Balm
- Chamomile
- Kava
- Berberine
- Chen Pi
- Astragalus
- Chrysanthemum
- Gamma-Aminobutyric Acid
- L-Theanine
- Luteolin
- Apigenin
- Anxiety
- Insomnia
- Liver Disease
- Liver Function Tests
Safety and disclaimer. This page is educational and is not medical advice. Neither Scutellaria lateriflora nor Scutellaria baicalensis is an established treatment for any disease, and the strength of evidence behind each stated use is labelled above so you can judge it yourself. There are no modern safety studies of either species in pregnancy or breastfeeding; American skullcap can add to the effect of sedatives, sleep or anti-anxiety medication, and alcohol; and either herb raises questions for people with liver disease, people taking a medication with a narrow safety margin, and people scheduled for surgery. Because “skullcap” on a label may be either species — or, historically, something else entirely — only a label that prints the binomial and the plant part and states that identity was verified tells the buyer what is inside. Fatigue, nausea, abdominal pain, dark urine, pale stools, or yellowing of the skin or eyes while taking any herbal product are signs of liver injury that hospitals treat as urgent.